Cell Therapy Market 2024 Key Strategies, Trends and Growth Opportunities, Historical Analysis, Segmentation | Allogene Therapeutics, Athersys, Inc

Market Overview:

Cell therapy involves using cells for therapeutic purpose. It includes various products used for treatment of various chronic diseases like cancer, neurological disorders, cardiovascular diseases.

Market Dynamics:

Rising prevalence of chronic diseases globally is expected to propel the growth of cell therapy market over the forecast period. According to WHO, chronic diseases accounted for over 60% of global deaths in 2016 and cardiovascular diseases were the leading cause of death globally, taking an estimated 17.9 million lives each year. Further, increasing investments in cell-based research is also anticipated to boost the market growth. Numerous public and private organizations are investing heavily in R&D of regenerative medicines involving cell and gene therapies for various diseases. For instance, National Institutes of Health invested around US$ 1.4 billion in regenerative medicine research in FY 2020.

Get an Exclusive Sample Copy of the Report at: - https://www.coherentmarketinsights.com/insight/request-sample/5413

Moreover, it will also include the opportunities available in micro markets for stakeholders to invest, a detailed analysis of the competitive landscape, and product services of key players. Analysis of Cell Therapy companies, key tactics followed by Leading Key Players:

◘ Bristol Myers Squibb Company
◘ Amgen Inc.
◘ Novartis AG
◘ Gilead Sciences Inc.
◘ Johnson & Johnson Services Inc.
◘ Allogene Therapeutics
◘ Athersys Inc.
◘ Orchard Therapeutics
◘ JW Therapeutics Co., Ltd.,
◘ Dendreon Pharmaceuticals LLC.
◘ Autolus Therapeutics
◘ APAC Biotech
◘ CORESTEM Inc.
◘ BioCardia Inc.
◘ JCR Pharmaceuticals Co., Ltd.,
◘ Oxford Biomedica
◘ CASI Pharmaceuticals Inc.

Two Major Drivers Propelling Growth in the Cell Therapy Market

Increasing prevalence of chronic diseases such as cancer is one of the key drivers augmenting the demand for cell therapies. Cancer burden has been steadily rising worldwide with an estimated 18.1 million new cancer cases and 9.6 million cancer deaths in 2018. Several cell-based therapies have shown promising results in treating various cancer types such as leukemia, lymphoma and multiple myeloma. This has encouraged investments into developing more advanced cell therapies for both hematological as well as solid tumors.

Another major factor fueling the cell therapy market expansion is the rising geriatric population globally. Aged population is more susceptible to various chronic and degenerative conditions. Cell therapies offer novel treatment approaches for diseases like Parkinson's and Alzheimer's for which no definitive cures exist currently. Several clinical studies have demonstrated the ability of cell therapies to regenerate damaged tissues and restore cell function. As life expectancy increases worldwide, the elderly patient pool requiring such regenerative interventions will continue growing. This rising geriatric demography is anticipated to drive sustained growth of the cell therapy market in the coming years.

One Key Market Restrain Hindering Broader Adoption

High Treatment Costs Pose Significant Barrier for Widespread Adoption of Cell Therapies

While cell therapy delivers promising clinical benefits, the high costs associated with these treatments limits broader access and adoption. Developing an effective cell therapy requires significant investments in R&D and clinical testing over many years. The complex manufacturing processes involving cell isolation, genetic modification, activation/expansion and quality testing further increases production costs. Additionally, many cell therapies require customization and large-scale expansion for individual patient use. These factors make the current list prices of approved cell therapies to range from hundreds of thousands to several million dollars per patient. Limited or no insurance coverage for such novel treatments poses severe financial burden on patients as well. Although costs may declines with anticipated manufacturing and process advancements, high treatment expenditures will likely remain a major market barrier at least in the near future hampering broader accessibility and uptake of this promising treatment modality.

Buy This Premium Report and Get Upto 25 % OFF: https://www.coherentmarketinsights.com/insight/buy-now/5413

One High-Potential Market Opportunity

Rising Focus on Personalized Medicine Creates Opportunities for Cell Therapies

The last few years have seen increasing emphasis on personalized and precision medicine approaches for more effective disease treatment. Advanced technologies like next-gen sequencing have enabled more in-depth understanding of individual molecular profiles that influence disease pathology and drug response. This has led to growing demand for customized treatment options. Cell therapies perfectly align with the concept of personalized medicine since they can be tailored to target specific patient characteristics or disease mutations. Many current cell therapy candidates also utilize patient's own cells (e.g. T-cells, stem cells) that are then modified ex vivo and reintroduced to induce targeted response. The paradigm shift towards personalized care provides significant opportunities for cell therapy developers to design and deliver more individualized treatment protocols. Going forward, the expanding personalized medicine sector will continue fueling new growth prospects and innovative applications of cell-based approaches.

One Key Market Trend - Focus on Combination Therapies

Continued Focus on Combination Therapies to Maximize Therapeutic Benefits

A notable trend gaining traction in the cell therapy area is the development of combination interventions that leverage synergies between multiple treatment modalities. Preclinical and early clinical studies indicate that combining cell therapies with other therapeutic agents like chemotherapeutics, targeted drugs or immunotherapy could help overcome certain limitations and augment clinical responses. For example, cell therapies are being combined with checkpoint inhibitors to boost anti-tumor immunity. Similarly, engineered CAR-T cells are being developed in combination with targeted tyrosine kinase inhibitors. The rationale is that cell therapies may synergize with other drugs to achieve better clinical outcomes through enhanced tumor targeting, prolonged persistence of therapeutic cells and reduced risk of resistance. Major industry players are making large investments into exploring various combination strategies. This growing focus on multi-modal approaches is expected to be a defining trend that helps address complex diseases more effectively and accelerate cell therapy commercialization.

Segment Details Analysis

By Therapy Type:

Stem Cells
T-cells
Dendritic Cells
NK-cells

By Indication:

Oncology
Cardiology
Neurology
Others

By End User:

Hospitals
Clinics
Research Institutes

The Study Objectives are:

A comprehensive insight into key players operating in the Cell Therapy Market and their corresponding data.
It includes product portfolio, annual revenue, expenditure on research and development, geographical presence, key developments in recent years, and growth strategies.
Regional analysis, which includes insight into the dominant market and corresponding market share.
It also includes various socio-economic factors affecting the evolution of the market in the region.
The report offers a comprehensive insight into different individuals from value chains such as raw materials suppliers, distributors, and stockholders.
Table of Contents:

Market scenario 2024

Chapter 1: Introduction, Market Driving Force Product Objective of Study and Research Scope the Cell Therapy market
Chapter 2: Exclusive Summary - the basic information of the Cell Therapy Market.
Chapter 3: Displaying the Market Dynamics- Drivers, Trends, and Challenges & Opportunities of the Cell Therapy
Chapter 4: Presenting the Cell Therapy Market Factor Analysis, Supply/Value Chain, PESTEL analysis, Market Entry, and Patent/Trademark Analysis.
Chapter 5: Displaying the by Type, End User, and Region/Country 2024 - 2031
Chapter 6: Evaluating the leading manufacturers of the Cell Therapy market which consists of its Competitive Landscape, Peer Group Analysis, Market positioning & Company Profile
Chapter 7: To evaluate the market by segments, by countries, and by Manufacturers/Companies with revenue share and sales by key countries in these various regions (2024-2031)
Chapters 8 & 9: Displaying the Appendix, Methodology, and Data Source

We Offer Customized Report, Click @ https://www.coherentmarketinsights.com/insight/request-customization/5413

Key Questions Answered:

What is the market size and CAGR of the Cell Therapy Market during the forecast period?
How is the growing demand impacting the growth of Cell Therapy Market shares?
What is the growing demand of the Market during the forecast period?
Who are the leading vendors in the market and what are their market shares?
What is the impact of the COVID-19 pandemic on the APAC Cell Therapy Market?

Contact Us

Mr. Shah
Coherent Market Insights Pvt Ltd,
533 Airport Boulevard, Suite 400, Burlingame,
CA 94010, United States
Phone: US +12067016702 / UK +4402081334027
JAPAN:+81-50-5539-1737
INDIA:+91-848-285-0837
Email: sales@coherentmarketinsights.com

About Coherent Market Insights

Coherent Market Insights is a global market intelligence and consulting organization that provides syndicated research reports, customized research reports, and consulting services. We are known for our actionable insights and authentic reports in various domains including aerospace and defense, agriculture, food and beverages, automotive, chemicals and materials, and virtually all domains and an exhaustive list of sub-domains under the sun. We create value for clients through our highly reliable and accurate reports. We are also committed in playing a leading role in offering insights in various sectors post-COVID-19 and continue to deliver measurable, sustainable results for our clients.

This release was published on openPR.